Dr. Stefanie Fischer
Medizinische Onkologie und Hämatologie · Dept. I
Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.
Boormans J, Sylvester R, Anson-Cartwright L, Glicksman R, Hamilton R, Hahn E, Daugaard G, Lauritsen J, Wagner T, Avuzzi B, Nicolai N, del Muro X, Aparicio J, Stalder O, Rothermundt C, Fischer S, Laguna M. Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office. Eur Urol Oncol 2023
Nov 9, 2023Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.
Nov 9, 2023Eur Urol Oncol 2023
Boormans Joost L, Sylvester Richard, Anson-Cartwright Lynn, Glicksman Rachel M, Hamilton Robert J, Hahn Ezra, Daugaard Gedske, Lauritsen Jakob, Wagner Thomas, Avuzzi Barbara, Nicolai Nicola, del Muro Xavier Garcia, Aparicio Jorge, Stalder Odile, Rothermundt Christian, Fischer Stefanie, Laguna Maria P
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Kelly W, Danila D, Lin C, Lee J, Matsubara N, Ward P, Armstrong A, Pook D, Kim M, Dorff T, Fischer S, Lin Y, Horvath L, Sumey C, Yang Z, Jurida G, Smith K, Connarn J, Penny H, Stieglmaier J, Appleman L. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov 2023:OF1-OF14.
Oct 20, 2023Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Oct 20, 2023Cancer Discov 2023:OF1-OF14
Kelly William K, Danila D C, Lin Chia-Chi, Lee Jae-Lyun, Matsubara Nobuaki, Ward Patrick J, Armstrong Andrew J, Pook David, Kim Miso, Dorff Tanya, Fischer Stefanie, Lin Yung-Chang, Horvath L G, Sumey Christopher, Yang Zhao, Jurida Gabor, Smith Kristen M, Connarn Jamie N, Penny Hweixian L, Stieglmaier Julia, Appleman Leonard J
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
Templeton A, Omlin A, Berthold D, Beyer J, Burger I, Eberli D, Engeler D, Fankhauser C, Fischer S, Gillessen S, Nicolas G, Kroeze S, Lorch A, Müntener M, Papachristofilou A, Schäfer N, Seiler D, Stenner-Liewen F, Tsantoulis P, Vlajnic T, Zilli T, Zwahlen D, Cathomas R. Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer. Swiss Med Wkly 2023; 153:40108.
Aug 15, 2023Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
Aug 15, 2023Swiss Med Wkly 2023; 153:40108
Templeton Arnoud J, Omlin Aurelius, Berthold Dominik R, Beyer Jörg, Burger Irene A, Eberli Daniel, Engeler Daniel, Fankhauser Christian Daniel, Fischer Stefanie, Gillessen Silke, Nicolas Guillaume, Kroeze Stephanie G C, Lorch Anja, Müntener Michael, Papachristofilou Alexandros, Schäfer Niklaus G, Seiler Daniel, Stenner-Liewen Frank, Tsantoulis Petros, Vlajnic Tatjana, Zilli Thomas, Zwahlen Daniel Rudolf, Cathomas Richard
Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study.
Silzle T, Kahlert C, Albrich W, Nigg S, Demmer-Steingruber R, Driessen C, Fischer S. Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study. Swiss Med Wkly 2023; 153:40090.
Jun 15, 2023Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study.
Jun 15, 2023Swiss Med Wkly 2023; 153:40090
Silzle Tobias, Kahlert Christian, Albrich Werner, Nigg Susanne, Demmer-Steingruber Ruth, Driessen Christoph, Fischer Stefanie
European Association of Urology Guidelines on Testicular Cancer: 2023 Update.
Patrikidou A, Cazzaniga W, Berney D, Boormans J, de Angst I, Di Nardo D, Fankhauser C, Fischer S, Gravina C, Gremmels H, Heidenreich A, Janisch F, Leão R, Nicolai N, Oing C, Oldenburg J, Shepherd R, Tandstad T, Nicol D. European Association of Urology Guidelines on Testicular Cancer: 2023 Update. Eur Urol 2023; 84:289-301.
May 12, 2023European Association of Urology Guidelines on Testicular Cancer: 2023 Update.
May 12, 2023Eur Urol 2023; 84:289-301
Patrikidou Anna, Cazzaniga Walter, Berney Daniel, Boormans Joost L, de Angst Isabel, Di Nardo Domenico, Fankhauser Christian Daniel, Fischer Stefanie, Gravina Carmen, Gremmels Hendrik, Heidenreich Axel, Janisch Florian, Leão Ricardo, Nicolai Nicola, Oing Christoph, Oldenburg Jan, Shepherd Robert, Tandstad Torgrim, Nicol David
Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment.
Menges D, Piatti M, Omlin A, Cathomas R, Benamran D, Fischer S, Iselin C, Kueng M, Lorch A, Prause L, Rothermundt C, O'Meara Stern A, Zihler D, Lippuner M, Braun J, Cerny T, Puhan M. Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment. Eur Urol Open Sci 2023; 51:26-38.
Mar 22, 2023Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment.
Mar 22, 2023Eur Urol Open Sci 2023; 51:26-38
Menges Dominik, Piatti Michela C, Omlin Aurelius, Cathomas Richard, Benamran Daniel, Fischer Stefanie, Iselin Christophe E, Kueng Marc, Lorch Anja, Prause Lukas, Rothermundt Christian, O'Meara Stern Alix, Zihler Deborah, Lippuner Max, Braun Julia, Cerny Thomas, Puhan Milo Alan
The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Seifert B, Alex Kluth L, Ufe M, Mingrone W, Templeton A, Fischer N, Rothschild S, Woelky R, Gillessen S, Cathomas R. The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. Eur Urol Open Sci 2023; 50:57-60.
Feb 20, 2023The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
Feb 20, 2023Eur Urol Open Sci 2023; 50:57-60
Fischer Stefanie, Rothermundt Christian, Stalder Odile, Terbuch Angelika, Hermanns Thomas, Zihler Deborah, Müller-Stich Beat P, Fankhauser Christian Daniel, Hirschi-Blickenstorfer Anita, Seifert Bettina, Alex Kluth Luis, Ufe Mark-Peter, Mingrone Walter, Templeton Arnoud J, Fischer Natalie Fischer, Rothschild Sacha I, Woelky Regina, Gillessen Silke, Cathomas Richard
Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
Neuenschwander A, Lonati C, Antonelli L, Papachristofilou A, Cathomas R, Rothermundt C, Templeton A, Gulamhusein A, Fischer S, Gillessen S, Hermanns T, Lorch A, Mattei A, Fankhauser C. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. Eur Urol Focus 2022
Nov 12, 2022Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
Nov 12, 2022Eur Urol Focus 2022
Neuenschwander Anne, Lonati Chiara, Antonelli Luca, Papachristofilou Alexandros, Cathomas Richard, Rothermundt Christian, Templeton Arnoud J, Gulamhusein Aziz, Fischer Stefanie, Gillessen Silke, Hermanns Thomas, Lorch Anja, Mattei Agostino, Fankhauser Christian D
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.
Fischer S, Götze T, Omlin A, Baird R, Dawson K, Zitt C, Arany Z, Tresch G, Fiedler U, Jeger S, Fung S, Legenne P, Leupin N, Schneeweiss A, Fremd C. A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab. JCO Precis Oncol 2022; 6:e2200006.
Nov 1, 2022A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.
Nov 1, 2022JCO Precis Oncol 2022; 6:e2200006
Fischer Stefanie, Götze Thorsten O, Omlin Aurelius, Baird Richard D, Dawson Keith M, Zitt Christof, Arany Zita, Tresch Gaby, Fiedler Ulrike, Jeger Simone, Fung Samson, Legenne Philippe, Leupin Nicolas, Schneeweiss Andreas, Fremd Carlo
Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018.
Aeppli S, Engeler D, Fischer S, Omlin A, Pratsinis M, Hermann C, Rothermundt C. Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018. Swiss Med Wkly 2022; 152:w30175.
Jun 16, 2022Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018.
Jun 16, 2022Swiss Med Wkly 2022; 152:w30175
Aeppli Stefanie, Engeler Daniel, Fischer Stefanie, Omlin Aurelius, Pratsinis Manolis, Hermann Christian, Rothermundt Christian
Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy.
Terbuch A, Posch F, Bauernhofer T, Jost P, Partl R, Stranzl-Lawatsch H, Baciarello G, Fizazi K, Giannatempo P, Verzoni E, Sweeney C, Ravi P, Tran B, Basso U, White J, Vincenzi B, Oing C, Cutuli H, Dieckmann K, Gamulin M, Chovanec M, Fankhauser C, Heidenreich A, Mohamad O, Thibault C, Fischer S, Gillessen S. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. Int J Radiat Oncol Biol Phys 2022; 113:825-832.
Apr 20, 2022Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy.
Apr 20, 2022Int J Radiat Oncol Biol Phys 2022; 113:825-832
Terbuch Angelika, Posch Florian, Bauernhofer Thomas, Jost Philipp J, Partl Richard, Stranzl-Lawatsch Heidi, Baciarello Giulia, Fizazi Karim, Giannatempo Patrizia, Verzoni Elena, Sweeney Christopher, Ravi Praful, Tran Ben, Basso Umberto, White Jeff, Vincenzi Bruno, Oing Christoph, Cutuli Hernan Javier, Dieckmann Klaus Peter, Gamulin Marija, Chovanec Michal, Fankhauser Christian Daniel, Heidenreich Axel, Mohamad Osama, Thibault Constance, Fischer Stefanie, Gillessen Silke
Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG).
Seidel C, Hentrich M, Zschäbitz S, Paffenholz P, Heidenreich A, Nestler T, Tran B, Fischer S, Daugaard G, Ochsenreither S, Brito M, Zengerling F, Schwab C, Bokemeyer C, Oing C. Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). World J Urol 2022; 40:355-361.
Jan 7, 2022Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG).
Jan 7, 2022World J Urol 2022; 40:355-361
Seidel Christoph, Hentrich Marcus, Zschäbitz Stefanie, Paffenholz Pia, Heidenreich Axel, Nestler Tim, Tran Ben, Fischer Stefanie, Daugaard Gedske, Ochsenreither Sebastian, Brito Margarida, Zengerling Friedemann, Schwab Constantin, Bokemeyer Carsten, Oing Christoph
Metastatic Prostate Cancer: Treatment Options.
Achard V, Putora P, Omlin A, Zilli T, Fischer S. Metastatic Prostate Cancer: Treatment Options. Oncology 2021; 100:48-59.
Nov 15, 2021Metastatic Prostate Cancer: Treatment Options.
Nov 15, 2021Oncology 2021; 100:48-59
Achard Vérane, Putora Paul Martin, Omlin Aurelius, Zilli Thomas, Fischer Stefanie
Swiss germ-cell cancer consensus recommendations
Beyer J, Stenner F, Spahn M, Seiler R, Rothermundt C, Roth B, Papachristofilou A, Omlin A, Lorch A, Honecker F, Hermanns T, Gross T, Gillessen S, Fischer S, Fankhauser C, Cathomas R, Bode P, Berthold D, Bührer E. Swiss germ-cell cancer consensus recommendations. Swiss Med Wkly 2021; 151
Aug 23, 2021Swiss germ-cell cancer consensus recommendations
Aug 23, 2021Swiss Med Wkly 2021; 151
Beyer Jörg, Stenner Frank, Spahn Martin, Seiler Roland, Rothermundt Christian, Roth Beat, Papachristofilou Alexandros, Omlin Aurelius, Lorch Anja, Honecker Friedemann, Hermanns Thomas, Gross Tobias, Gillessen Silke, Fischer Stefanie, Fankhauser Christian D, Cathomas Richard, Bode Peter-Karl, Berthold Dominik, Bührer Emanuel
Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
Fankhauser C, Tandstad T, Nicolai N, Nicol D, Leão R, Muilwijk T, Janisch F, Mayor de Castro J, Gremmels H, Fizazi K, Fischer S, Boormans J, Bokemeyer C, Algaba F, Albers P, Oldenburg J, Pilar Laguna M. Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. Eur Urol 2021; 80:4-6.
Mar 12, 2021Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
Mar 12, 2021Eur Urol 2021; 80:4-6
Fankhauser Christian Daniel, Tandstad Torgrim, Nicolai Nicola, Nicol David, Leão Ricardo, Muilwijk Tim, Janisch Florian, Mayor de Castro Javier, Gremmels Hendrik, Fizazi Karim, Fischer Stefanie, Boormans Joost L, Bokemeyer Carsten, Algaba Ferran, Albers Peter, Oldenburg Jan, Pilar Laguna M
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
Baird R, Fischer S, Azaro A, Harstrick A, Stumpp M, Leupin N, Dawson K, Fiedler U, Zitt C, Rodón J, Harris A, Lord S, Middleton M, Linossi C, Omlin A. First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. J Clin Oncol 2020; 39:145-154.
Dec 10, 2020First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
Dec 10, 2020J Clin Oncol 2020; 39:145-154
Baird Richard D, Fischer Stefanie, Azaro Analia, Harstrick Andreas, Stumpp Michael T, Leupin Nicolas, Dawson Keith M, Fiedler Ulrike, Zitt Christof, Rodón Jordi, Harris Adrian, Lord Simon, Middleton Mark, Linossi Constanza, Omlin Aurelius
Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer
Fischer S, Clements S, McWilliam A, Green A, Descamps T, Oing C, Gillessen Sommer S. Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer. Cancer Treat Res Commun 2020; 25:100256.
Dec 1, 2020Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer
Dec 1, 2020Cancer Treat Res Commun 2020; 25:100256
Fischer Stefanie, Clements Sebastian, McWilliam Alan, Green Andrew, Descamps Tine, Oing Christoph, Gillessen Sommer Silke
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
Aeppli S, Sternberg C, Schmidinger M, Rini B, Porta C, Omlin A, Oldenburg J, McDermott D, Gruenwald V, Larkin J, Fischer S, Escudier B, Eisen T, Eboulet E, Rothermundt C. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. ESMO Open 2020; 5
Jan 1, 2020Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
Jan 1, 2020ESMO Open 2020; 5
Aeppli Stefanie, Sternberg Cora, Schmidinger Manuela, Rini Brian, Porta Camillo, Omlin Aurelius, Oldenburg Jan, McDermott David, Gruenwald Viktor, Larkin James, Fischer Stefanie, Escudier Bernard, Eisen Tim, Eboulet Eric Innocents, Rothermundt Christian
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma
Fischer S, Langberg C, Ståhl O, Fankhauser C, Hamid A, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen Sommer S, Wheater M, Hentrich M, Heidenreich A, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Global Germ-Cell Cancer Group. Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. J Clin Oncol 2019:JCO1901876.
Dec 26, 2019Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma
Dec 26, 2019J Clin Oncol 2019:JCO1901876
Fischer Stefanie, Langberg Carl W, Ståhl Olof, Fankhauser Christian Daniel, Hamid Anis A, Koutsoukos Konstantinos, Shamash Jonathan, White Jeff, Bokemeyer Carsten, Beyer Jörg, Gillessen Sommer Silke, Wheater Matthew, Hentrich Marcus, Heidenreich Axel, Tandstad Torgrim, Cohn-Cedermark Gabriella, Thibault Constance, Vincenzi Bruno, Klingbiel Dirk, Albany Costantine, Necchi Andrea, Terbuch Angelika, Lorch Anja, Aparicio Jorge, Global Germ-Cell Cancer Group
Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma
Fischer S, Ali O, Jochum W, Kluckert J, Flatz L, Siano M. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. Oncol Res Treat 2018; 41:391-394.
May 3, 2018Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma
May 3, 2018Oncol Res Treat 2018; 41:391-394
Fischer Stefanie, Ali Omar H, Jochum Wolfram, Kluckert Jörg-Thomas, Flatz Lukas, Siano Marco